证券代码：301262 证券简称：海看股份 公告编号：2025-020 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 海看网络科技（山东）股份有限公司（以下简称"公司"）2024年年度权益 分派方案已获得公司于2025年6月18日召开的2024年年度股东大会审议通过，现 将权益分派事宜公告如下： 一、股东大会审议通过权益分派方案情况 1、公司 2024 年年度股东大会审议通过的权益分派方案为：以公司总股本 417,000,000 股为基数，向全体股东每 10 股派发现金红利人民币 0.500000 元（含 税），总计派发现金红利人民币 20,850,000.00 元（含税）。本次不进行送股及资 本公积转增股本。若在利润分配方案实施前公司的股本发生变动，则以实施分配 方案时股权登记日的总股本为基数，公司将按照"现金分红总额固定不变"的原 则对分配比例进行调整。 2、自分派方案披露至实施期间，公司股本总额未发生变化。本次实施的权 益分派方案与 2024 年年度股东大会审议通过的利润分配预案一致。 3、本次实施分派方案距离股东大会审议通过的时间未超过两个月。 二 ...

关于海看网络科技（山东）股份有限公司 北京德和衡律师事务所 北京德和衡律师事务所 关于海看网络科技（山东）股份有限公司 2024年年度股东大会的 法律意见书 德和衡证见意见（2025）第144号 中国·北京市朝阳区建国门外大街 2 号银泰中心 C 座 11、12 层 电话： (+86 10) 8540 7666 邮编：100022 www.deheheng.com 北京德和衡律师事务所 BEIJING DHH LAW FIRM 2024年年度股东大会的 法律意见书 德和衡证见意见（2025）第144号 致：海看网络科技（山东）股份有限公司 北京德和衡律师事务所（以下简称"本所"）接受海看网络科技（山东）股份有限公司（以 下简称"公司"或"贵公司"）的委托，指派本所律师出席贵公司 2024 年年度股东大会。本 所律师依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）、 《海看网络科技（山东）股份有限公司章程》（以下简称"《公司章程》"）及相关法律法规 以及规范性文件的规定，就本次股东大会的有关事宜出具 ...

证券代码：301262 证券简称：海看股份 公告编号：2025-019 海看网络科技（山东）股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 1、 本次股东大会不存在否决议案的情形。 2、 本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、 召开时间： （1）现场会议：2025 年 6 月 18 日（星期三）15:00 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 6 月 18 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深 圳证券交易所互联网投票系统投票的具体时间为 2025 年 6 月 18 日 9:15-15:00。 2、 现场会议召开地点：山东省济南市历下区经十路 9777 号鲁商国奥城 5 号楼公司 3719 会议室 3、 召开方式：现场结合网络 4、 召集人：董事会 5、 主持人：董事长张先先生 6、 本次会议的召集、召开符合《中华人民共和国公司法》《上市公司股东 会规则》《深圳证券交易所 ...

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform" [1] Core Insights - The domestic innovative drug sector is entering a harvest phase with multiple new drug approvals, enhancing the focus on innovative drugs. As of the end of May 2025, a total of 53 new drugs were approved in China, including 30 domestic and 23 imported drugs, covering various treatment areas such as oncology and rare diseases. The upcoming national medical insurance negotiations are expected to accelerate the market entry of successfully approved innovative drugs [4][12][20]. Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 7699.75, with a weekly high of 8490.25 and a low of 6070.89 [1]. Recent Performance - The pharmaceutical and biotechnology sector increased by 2.21% this week, outperforming the CSI 300 index by 3.3 percentage points. Since May 2025, the sector has risen by 7.25%, again surpassing the CSI 300 index by 5.53 percentage points [16][19]. Subsector Performance - The biopharmaceutical sector saw the highest increase of 4.65%, followed by chemical preparations at 4.27%, and medical research outsourcing at 4%. The offline pharmacy sector experienced the largest decline at 2.69% [5][18]. Recommended and Benefiting Stocks - Recommended stocks include: Yingke Medical, Maipu Medical, Yihe Jiaye, Weidian Biology, Gongdong Medical, and others. Benefiting stocks include: Shanhaishan, Yirui Technology, and others [6][25][36]. Key Events and Trends - The approval of innovative drugs is expected to reshape valuations in the domestic innovative drug sector, which is anticipated to be a key investment theme throughout the year. The upcoming national medical insurance negotiations are crucial for the successful market entry of newly approved drugs [4][12][20]. Market Dynamics - The medical device sector is projected to benefit from policies promoting equipment upgrades, with a significant increase in procurement expected in the second quarter of 2025. The sector's current price-to-earnings ratio indicates potential for valuation growth [21][27]. Future Outlook - The report emphasizes the importance of monitoring procurement progress and the potential for a recovery in the medical device sector's performance in the coming quarters [21][23]. Conclusion - The pharmaceutical and biotechnology industry is positioned for growth, driven by innovative drug approvals and supportive policy changes, making it an attractive investment opportunity [4][12][20].

Meeting Information - The company will hold the 2024 Annual General Meeting on June 18, 2025, at 15:00, combining on-site voting and online voting [1][2] - The online voting will be available through the Shenzhen Stock Exchange trading system and the internet voting system from 9:15 to 15:00 on the same day [1][2] Voting Rights and Procedures - Only shareholders holding voting shares as of the registration date can attend the meeting and vote, either in person or by proxy [2][3] - Shareholders can choose either on-site voting or online voting, and duplicate votes will be counted as the first valid vote [2][3] Agenda Items - The meeting will discuss various proposals, all of which require a simple majority for approval [2] - Independent directors will present their annual reports, which will be discussed but not voted on [2] Registration and Attendance - Shareholders must present valid identification and proof of shareholding to register for the meeting [3][4] - Proxy representatives must provide additional documentation, including a power of attorney [3][4] Online Voting Process - The voting code is "351262," and shareholders can express their opinions as agree, disagree, or abstain [7] - Specific procedures for voting through the Shenzhen Stock Exchange trading system and internet voting system are outlined [7]

证券代码：301262 证券简称：海看股份 公告编号：2025-018 （2）网络投票： 海看网络科技（山东）股份有限公司 关于召开 2024 年年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 海看网络科技（山东）股份有限公司（以下简称"公司"）定于2025年6月18 日（星期三）15:00召开2024年年度股东大会，本次会议采取现场表决与网络投票 相结合的方式召开，现将有关事项通知如下： 一、召开会议的基本情况 1、会议届次：2024 年年度股东大会 2、会议召集人：公司董事会。第二届董事会第十六次会议审议通过了关于 召开本次股东大会的议案。 3、会议召开的合法、合规性：本次会议的召开符合有关法律、行政法规、 部门规章、规范性文件和《公司章程》的有关规定。 4、会议召开的日期、时间： （1）现场会议：2025 年 6 月 18 日（星期三）15:00 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 6 月 18 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00； 通过深圳证券交易所 ...

Core Insights - The company Haikan Network Technology (Shandong) Co., Ltd. has been recognized as one of the "Top 30 Growth Cultural Enterprises" in China, reflecting its commitment to integrating social and economic benefits while advancing the national cultural digital strategy [1] Group 1: Company Recognition and Achievements - Haikan Network has been acknowledged for its long-term efforts in promoting the integration of culture and technology, and for creating new business models in the cultural industry [1] - The company is a key enterprise under Shandong Radio and Television Station and has been listed among the top 100 internet companies in China six times [1] - In 2023, Haikan Network became the first broadcasting and television new media company to be listed on the Shenzhen Stock Exchange's ChiNext board under the registration system [1] Group 2: Market Position and Innovations - The company operates as the exclusive market operator for the Shandong IPTV integrated broadcasting and control platform, serving nearly 17 million users and offering over 270 high-definition channels and more than 400,000 hours of on-demand content [2] - Haikan Network has launched the first all-in-one smart TV in the industry, simplifying the user experience by eliminating the need for multiple remote controls and cables [2] Group 3: Content Production and Development - The company is one of the first state-owned cultural enterprises to invest in micro-short drama production, having produced over 150 micro-short dramas in collaboration with local partners [3] - Haikan Network has developed an intelligent review platform for micro-short dramas, addressing common issues related to value orientation in content [3] Group 4: Technological Innovation - The company prioritizes technological innovation, having established multiple innovation platforms and participated in significant national research projects, resulting in over 300 patents and software copyrights [4] - Haikan Network has developed an AI-based content review system to ensure safe broadcasting and has created a multimodal AIGC intelligent creation platform to promote traditional Chinese culture [4]

Core Viewpoint - The financial performance of Haikan Co., a subsidiary of Shandong Broadcasting, shows a slight decline in revenue and net profit for 2024, but a strong recovery in Q1 2025 with a significant increase in net profit margin, indicating a robust operational capability despite challenges in the micro-short drama segment [1][3][16]. Financial Overview - In 2024, the company achieved total revenue of 979 million yuan, a year-on-year decrease of 1.37%, and a net profit of 400 million yuan, down 2.38% year-on-year [3]. - For Q1 2025, the company reported revenue of 235 million yuan, a year-on-year decline of 5.19%, but net profit increased by 7.45% to 117 million yuan [3]. - The net profit margin remained above 40% for the past year, exceeding 50% in Q1 2025, attributed to the monopoly nature of its IPTV business [3][16]. Business Structure - IPTV business, the core revenue driver, contributed over 95% of total revenue, with basic IPTV services generating 795 million yuan (up 0.02%) and value-added services declining by 14.61% to 139 million yuan [3]. - The micro-short drama business is still in its infancy, with the subsidiary Baizhua Yule reporting a net profit of only 1,758.88 yuan in 2024 [3][16]. Short Drama Business Layout - The company has established a comprehensive micro-short drama strategy, including a production base and a product matrix, but actual profitability remains limited [8][16]. - The Northern Micro-Short Drama Film and Television Base serviced over 100 micro-short drama crews and produced 102 short dramas in 2024 [8]. - The company has launched several platforms for distribution, including "Octopus Small Theater" on WeChat and Douyin, but faces challenges in mobile presence due to limited content and lack of marketing investment [9][11]. Content Strategy - The company focuses on a "micro-short drama +" model, producing legal-themed short dramas and exploring various themes such as anti-fraud and cultural tourism [12][16]. - Despite producing a limited number of original micro-short dramas, the company has invested in over 1,000 second-round copyright dramas [15][16]. Competitive Landscape - The company benefits from its strong IPTV user base of approximately 16.85 million households, providing a unique advantage in promoting micro-short dramas on large screens [16]. - However, competition in the micro-short drama market is intensifying, with established players having developed effective content and monetization strategies, posing challenges for Haikan as a latecomer [16].

Financial Performance - The company reported a total revenue of 9.79 billion yuan in 2024, a decrease of 1.37% year-on-year [6] - The net profit attributable to shareholders for 2024 was 4.00 billion yuan, down 2.38% compared to the previous year [6] - In Q1 2025, the company achieved a revenue of 2.35 billion yuan, with a net profit of 1.17 billion yuan, reflecting a year-on-year growth of 7.45% [6] IPTV Business Development - The IPTV basic business revenue for 2024 was 795 million yuan, showing a slight increase of 0.02% year-on-year [2] - The number of effective IPTV users reached 16.85 million [2] - The company plans to enhance its IPTV services through innovation and collaboration with major telecom operators [2] Strategic Advantages - The company is the exclusive IPTV operator in Shandong province, benefiting from a large user base and market penetration potential [3] - It is focusing on transforming traditional TV viewing into interactive services, integrating various public services [3] - The company is investing in AI technology to improve content creation and operational efficiency [5] Capital Investment Strategy - The company aims to invest in new products, technologies, and business models that extend its existing industry chain [4] - In 2021, the company invested 15 million yuan to establish a joint venture, holding a 27.78% stake [4] - The company is exploring diverse capital operation methods to enhance its competitive edge [4] Dividend Policy - The company has implemented four cash dividend distributions since its listing, totaling 620 million yuan [6] - For 2024, the proposed dividend is 0.50 yuan per 10 shares, based on a total share capital of 417 million shares [6] - The company emphasizes a sustainable dividend policy while ensuring financial health and shareholder returns [6] Taxation and Policy Context - The company currently does not benefit from the tax exemption policy for cultural enterprises but is actively pursuing recognition for this status [7] - The recent policy changes are expected to enhance the competitiveness of cultural enterprises [7]

Summary of the Conference Call for Yizhi Konjac Company Overview - Yizhi Konjac primarily engages in deep processing of konjac, with three main product lines: konjac powder, konjac food, and konjac beauty products. Konjac powder constitutes 70% of the revenue in 2024, with sales exceeding 6,000 tons and a global market share of 12%, leading the market [2][3][4]. Industry Insights - The konjac food segment, including snacks and tea additives, accounts for 28% of revenue, with rapid growth driven by health trends, particularly the "konjac crystal ball" favored by brands like Mixue Ice City [2][4]. - The konjac industry in China consists of four main segments: planting, initial processing, deep processing, and application. The deep processing segment is primarily focused on food but also extends to chemical, skincare, and medical applications [12]. Financial Performance and Projections - Yizhi Konjac is expected to benefit from rising raw material prices and overseas replenishment demand, projecting a revenue growth of over 15% in 2025, with potential for over 50% growth if external orders are secured [2][5]. - Forecasted net profits for 2025, 2026, and 2027 are 98 million, 126 million, and 174 million yuan respectively, with a compound annual growth rate exceeding 30% [2][6]. - The company's current valuation corresponds to a PE ratio of approximately 48 for 2025, which is above historical averages [6][23]. Cost Structure and Profitability - The gross margin is influenced by raw material prices, inventory levels, and procurement strategies. Historically, the gross margin has improved significantly, with a notable increase of nearly 4 percentage points in 2024 [8][9]. - The company has seen a decrease in expense ratios from 22.7% in 2014 to 10.2% in 2020, but this has increased due to expansion efforts [9]. Market Dynamics - The konjac raw material prices are primarily driven by demand, with expectations for prices to remain high or increase further in 2025 due to a projected 20% growth in downstream applications [13][14]. - China is a major producer of konjac, with annual production increases of 10%-20%. However, supply constraints due to seed shortages and adverse weather conditions are anticipated [14][16]. Competitive Landscape - Major competitors in the konjac market include Yizhi Konjac, Yizhi Magic, and others, with leading companies enhancing customer loyalty through vertical and horizontal integration [17][18]. - The company has established strong procurement relationships and a proprietary technology system, allowing for high-value konjac micro-powder production with a gross margin of 20%-25% [16]. Growth Drivers - Future growth is expected to stem from advancements in blending technology in mature markets and the exploration of new applications in pet food and health products [18][22]. - The company is positioned to capitalize on the rapid growth of the konjac snack and tea additive markets, benefiting from integrated service advantages and strong raw material control [18][21]. Overall Outlook - The company is anticipated to benefit from both supply and demand dynamics in the short term, with a strong potential for long-term growth driven by industry upgrades and increased market penetration [24].